Related references
Note: Only part of the references are listed.Ecallantide: An alternative treatment of refractory angioedema in adolescents with systemic lupus erythematosus
Watcharoot Kanchongkittiphon et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)
Engineered Protein Scaffolds as Next-Generation Therapeutics
Michaela Gebauer et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 60 (2020)
Evolutionary Aspects of the Structural Convergence and Functional Diversification of Kunitz-Domain Inhibitors
Manasi Mishra
JOURNAL OF MOLECULAR EVOLUTION (2020)
Selective brain hypothermia-induced neuroprotection against focal cerebral ischemia/reperfusion injury is associated with Fis1 inhibition
Ya-Nan Tang et al.
NEURAL REGENERATION RESEARCH (2020)
Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass
Valerie Pireaux et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
A novel protease-activated receptor 1 inhibitor from the leech Whitmania pigra
Ren Shen-Hong et al.
CHINESE JOURNAL OF NATURAL MEDICINES (2019)
In vitro-engineered non-antibody protein therapeutics
Rudo Simeon et al.
PROTEIN & CELL (2018)
Characterization of a Kunitz trypsin inhibitor from Enterolobium timbouva with activity against Candida species
Caio F. R. de Oliveira et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2018)
Artificial Anti-Tumor Opsonizing Proteins with Fibronectin Scaffolds Engineered for Specificity to Each of the Murine FcγR Types
Tiffany F. Chen et al.
JOURNAL OF MOLECULAR BIOLOGY (2018)
Novel Kunitz-like Peptides Discovered in the Zoanthid Palythoa caribaeorum through Transcriptome Sequencing
Qiwen Liao et al.
JOURNAL OF PROTEOME RESEARCH (2018)
Purification and Characterization of a Novel Antiplatelet Peptide from Deinagkistrodon acutus Venom
Yi Kong et al.
TOXINS (2018)
2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants
Gordon F. Tomaselli et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Faster, deeper, smaller-the rise of antibody-like scaffolds
Brian Owens
NATURE BIOTECHNOLOGY (2017)
Neuroprotection of Catalpol for Experimental Acute Focal Ischemic Stroke: Preclinical Evidence and Possible Mechanisms of Antioxidation, Anti-Inflammation, and Antiapoptosis
Xia-wei Zheng et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2017)
The Pfam protein families database: towards a more sustainable future
Robert D. Finn et al.
NUCLEIC ACIDS RESEARCH (2016)
Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk
Weifei Zhu et al.
CELL (2016)
The Coagulation Factor XIIa Inhibitor rHA-Infestin-4 Improves Outcome after Cerebral Ischemia/Reperfusion Injury in Rats
Jennifer Krupka et al.
PLOS ONE (2016)
The Menagerie of Human Lipocalins: A Natural Protein Scaffold for Molecular Recognition of Physiological Compounds
Andre Schiefner et al.
ACCOUNTS OF CHEMICAL RESEARCH (2015)
Comparison of protein repeat classifications based on structure and sequence families
Lisanna Paladin et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2015)
Challenges and opportunities for non-antibody scaffold drugs
Rodrigo Vazquez-Lombardi et al.
DRUG DISCOVERY TODAY (2015)
A Novel Direct Factor Xa Inhibitory Peptide with Anti-Platelet Aggregation Activity from Agkistrodon acutus Venom Hydrolysates
Meimei Chen et al.
SCIENTIFIC REPORTS (2015)
Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity
W. Chen et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Review article: linaclotide for the management of irritable bowel syndrome with constipation
P. Layer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Desmolaris, a novel factor XIa anticoagulant from the salivary gland of the vampire bat (Desmodus rotundus) inhibits inflammation and thrombosis in vivo
Dongying Ma et al.
BLOOD (2013)
Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice
Martina Morowski et al.
BLOOD (2013)
The venom optimization hypothesis revisited
David Morgenstern et al.
TOXICON (2013)
Ecallantide for treatment of acute attacks of hereditary angioedema
Jay L. Martello et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2012)
The kunitz protease inhibitor domain of protease nexin-2 inhibits factor XIa and murine carotid artery and middle cerebral artery thrombosis
Wenman Wu et al.
BLOOD (2012)
Anti-inflammatory effects of DX-890, a human neutrophil elastase inhibitor
Fiona K. Dunlevy et al.
JOURNAL OF CYSTIC FIBROSIS (2012)
Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept
Thierry Wurch et al.
TRENDS IN BIOTECHNOLOGY (2012)
Non-immunoglobulin based protein scaffolds
John Lofblom et al.
CURRENT OPINION IN BIOTECHNOLOGY (2011)
Factor XI and XII as antithrombotic targets
Felicitas Mueller et al.
CURRENT OPINION IN HEMATOLOGY (2011)
A New Risk Scheme to Predict Warfarin-Associated Hemorrhage The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study
Margaret C. Fang et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis
Ophira Salomon et al.
THROMBOSIS AND HAEMOSTASIS (2011)
EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema
Robyn J. Levy et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2010)
Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain
Howard Howard Smith
Therapeutics and Clinical Risk Management (2010)
FN3: a new protein scaffold reaches the clinic
Laird Bloom et al.
DRUG DISCOVERY TODAY (2009)
Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis
Yves Decrem et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Reduced incidence of ischemic stroke in patients with severe factor XI deficiency
Ophira Salomon et al.
BLOOD (2008)
Display scaffolds: protein engineering for novel therapeutics
Stewart D. Nuttall et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery
Andreas Lehmann
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor
Lynda Schneider et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2007)
Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice
X. Wang et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis
Sylvie Attucci et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
A new generation of protein display scaffolds for molecular recognition
RJ Hosse et al.
PROTEIN SCIENCE (2006)
Structural and mutational analyses of the molecular interactions between the catalytic domain of factor XIa and the Kunitz protease inhibitor domain of protease nexin 2
D Navaneetham et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice
X Wang et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Lipocalins in drug discovery: from natural ligand-binding proteins to 'anticalins'
S Schlehuber et al.
DRUG DISCOVERY TODAY (2005)
Adaptive evolution in the snake venom Kunitz/BPTI protein family
V Zupunski et al.
FEBS LETTERS (2003)
Protease inhibitors: Current status and future prospects
D Leung et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
